



CASE TX/4-32732A *1 fu*

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV72248820045  
Express Mail Label Number

February 16, 2007  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

VON MATT ET AL.

Examiner: Kosack, Joseph R

APPLICATION NO: 10/542,175

FILED: JULY 14, 2005

FOR: INDOLYLMALEIMIDE DERIVATIVES

**MS: Petition**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


**PETITION UNDER 37 CFR § 1.144**

**BACKGROUND OF THE PETITION**

In the Office Action dated August 1, 2006 the claims in the present application were held subject to restriction. In Applicants' response mailed October 18, 2006, the restriction was traversed and reconsideration of the restriction requirement was requested. In the subsequent Office Action dated December 20, 2006, the restriction requirement was made FINAL. Therefore, this Petition is believed to be proper.

## RELEVANT CLAIMS AT ISSUE

Claim 1. A compound of formula I





wherein

R<sub>a</sub> is H; C<sub>1-4</sub>alkyl; or C<sub>1-4</sub>alkyl substituted by OH, NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl or N(di-C<sub>1-4</sub>alkyl)<sub>2</sub>;

R<sub>b</sub> is H; halogen; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkoxy, and

R is a radical of formula (a) or (b)



wherein

each of R<sub>1</sub> and R<sub>3</sub> is a heterocyclic residue; or a radical of formula α



wherein X is a direct bond, O, S or NR<sub>11</sub> wherein R<sub>11</sub> is H or C<sub>1-4</sub>alkyl,

R<sub>c</sub> is C<sub>1-4</sub>alkylene or C<sub>1-4</sub>alkylene wherein one CH<sub>2</sub> is replaced by CR<sub>x</sub>R<sub>y</sub> wherein one of R<sub>x</sub> and R<sub>y</sub> is H and the other is CH<sub>3</sub>, each of R<sub>x</sub> and R<sub>y</sub> is CH<sub>3</sub> or R<sub>x</sub> and R<sub>y</sub> form together -CH<sub>2</sub>-CH<sub>2</sub>-,

Y is bound to the terminal carbon atom and is selected from OH, -NR<sub>12</sub>R<sub>13</sub> wherein each of R<sub>12</sub> and R<sub>13</sub>, independently, is H, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, aryl, aryl-C<sub>1-4</sub>alkyl, heteroaryl-C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl or C<sub>1-4</sub>alkyl optionally substituted on the terminal carbon atom by OH, halogen, C<sub>1-4</sub>alkoxy or -NR<sub>14</sub>R<sub>15</sub> wherein each of R<sub>14</sub> and R<sub>15</sub>, independently, is H, C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, aryl-C<sub>1-4</sub>alkyl, or R<sub>12</sub> and R<sub>13</sub> form together with the nitrogen atom to which they are bound a heterocyclic residue; and

each of R<sub>2</sub> and R<sub>4</sub>, independently, is H; halogen; C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkoxy; CF<sub>3</sub>; nitrile; nitro or amino, or a salt thereof.

Claim 2. A compound according to claim 1 wherein  $R_a$  is H, methyl, ethyl, or isopropyl, or a salt thereof.

Claim 3. A compound according to claim 1 wherein  $R_b$  is H, Cl, methyl or ethyl, or a salt thereof.

Claim 4. A compound of claim 1 wherein  $R_1$  is a heterocyclic residue, e.g. a piperazinyl, optionally substituted on a ring nitrogen or on a ring carbon, e.g. 4-methyl-piperazin-1-yl, or 4,7-diaza-spiro[2.5]oct-7-yl; or a radical of formula ( $\alpha$ ) wherein X is a direct bond,  $R_c$  is  $CH_2$  and Y is  $-NR_{12}R_{13}$  wherein each of  $R_{12}$  and  $R_{13}$ , independently, is H,  $C_{3-6}$ cycloalkyl- $C_{1-4}$ alkyl,  $C_{2-6}$ alkenyl or  $C_{1-4}$ alkyl optionally substituted on the terminal carbon atom by OH, halogen,  $C_{1-4}$ alkoxy or  $-NR_{14}R_{15}$  wherein each of  $R_{14}$  and  $R_{15}$ , independently, is H or  $C_{1-4}$ alkyl; or  $R_{12}$  and  $R_{13}$  form together with the nitrogen atom to which they are bound a heterocyclic residue e.g. a piperazinyl, or a salt thereof.

Claim 5. A compound of claim 1 wherein  $R_2$  and/or  $R_4$  is H; Cl, F;  $CF_3$ ; nitrile; nitro or amino, or a salt thereof.

## **RESTRICTION REQUIREMENT**


The following is repeated from the August 1, 2006 Office Action:

### **Election/Restrictions**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.


Due to the numerous variables in the claims, e.g.  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , etc...and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein the formula is




where  $R_a$ ,  $R_6$ , and  $R_7$  are H;  $R_b$  and  $R_5$  are methyl; and  $R_2$  is  $CF_3$ .

Group II, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein the formula is




where  $R_a$ ,  $R_b$ ,  $R_2$ ,  $R_6$ , and  $R_7$  are H; and  $R_5$  is methyl.

Group III, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein the formula is




where  $R_a$ ,  $R_b$ , and  $R_5$  are H;  $R_6$ , and  $R_7$  joined together by  $\text{CH}_2\text{-CH}_2$ , and  $R_2$  is  $\text{CF}_3$ .

Group IV, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds to Formula I and their pharmaceutical composition wherein the formula is




where  $R_a$ ,  $R_b$ , and  $R_8$  are H;  $R_4$  is Cl; and  $R_9$  is  $\text{CH}_2\text{-cyclopropyl}$ .

Group V, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein the formula is



where  $R_a$ ,  $R_b$ , and  $R_8$  are H;  $R_4$  is Cl; and  $R_9$  is  $\text{CH}_2\text{-CH}_2\text{F}$ .

Group VI, claim(s) 1-5 (in part) and 7-9 (in part), drawn to compounds of Formula I and their pharmaceutical composition wherein the formula is



where  $R_a$  and  $R_b$  are H;  $R_4$  is Cl; and  $R_8$  and  $R_9$  are joined together by  $-CH_2-CH_2-N-CH_2-CH_2-$ .

Group VII, claim(s) 6, drawn to a method of preparation of compounds of Formula I.

Group VIII, claim(s) 10, drawn to methods of use of compounds of Formula I.

In accordance with 37 CFR 1.499, Applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again, **this list is not exhausted**, as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, Applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and Examiner will endeavor to group the same. **If Applicant is unable to elect a single invention, Applicant may instead choose to elect a specific compound and Examiner will attempt to group it.**

## **ARGUMENT**

It is stated in the Office Action of August 1, 2006, that the application claims groups of inventions that are not so limited to form a general concept under PCT Rule 13.1 Set forth in the Office Action are eight groups of inventions (Groups I through VIII) which are said to be "exemplary". It is expressly acknowledged in the Office Action that the eight groups are not exhaustive.

Applicants were offered the alternative, instead of electing one of the eight groups expressly set forth, to elect a specific compound and "Examiner will attempt to group it". Applicants choose to take the latter course of action, i.e., to elect a compound not encompassed in any of the compound claims of the eight groups. Applicants provisionally elected the compound of Example 1, i.e., 3-(1H-Indol-3-yl)-4-[6-(4-methyl-piperazin-1-yl)-3-trifluoromethyl-pyridin-2-yl]-pyrrole-2,5-dione. To be clear, the traverse was as the restriction is applied to the compound claims (Groups I-VI); the restriction among compound claims (I-VI), method of preparation (Group VII) and method of use (Group VIII) was not traversed.

Applicants submit that it is improper for the Patent Office to set forth a restriction requirement that is merely "exemplary". Applicants are entitled to know the full scope of the restriction requirement before being requested to make an election. MPEP § 814 and 815 specifically require that the restriction requirement must be clear and detailed (§ 814) and must be complete (§ 815). The present restriction is neither. The "non-exemplary" undefined groups can have a significant bearing on the group chosen for election. Indeed, in the present provisional election, Applicants included Example 1, which is not even encompassed by any of the compound claims in the eight groups set forth in the Office Action. Furthermore, Applicants are mystified by the alternative offered by the Examiner, i.e., to elect a single compound and the "Examiner will attempt to group it". Looking at Group I, for instance, the "Group" is a single species. The Examiner followed this pattern in the Office Action of December 20, 2006, the elected "Group" was a single species, i.e., the provisionally elected compound of Example 1. Such a restriction group containing only a single species is manifestly unfair, is in direct conflict with the PCT rules of unity of invention and is a contrary to Patent Office practices and procedures. Annex B, Unity of invention, of the PCT rules and Chapter 10 of the "PCT International Search and Preliminary Examination Guidelines" (copy attached) clearly set forth the requirements of a generic compound claim under "Markush Practice" to meet the unity of invention standard. These requirements are that 1.) all the alternatives have a common property or activity and 2.) a common, significant structural element is shared by all of the alternatives. Applicants' claims 1-5 (Group I-VI), and the undefined "groups" not encompassed by I-VI, clearly meet both of the PCT requirements in order for the Unity of Invention to exist.

It is submitted that the reasons set forth in the Office action of August 1, 2006 at the bottom of page 5 of the August 1, 2006 Office Action regarding U.S. patent number 5,057,614 are not determinative. The cited Example 87 of the '614 patent is not relevant to unity of invention for the present claims. Chapter 10 of the above-noted PCT Guidelines states:

With respect to a group of inventions claimed in an international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" is defined in Rule 13.2 as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art. The determination is made on the contents of the claims as interpreted in light of the description and drawings (if any).

It is submitted that Applicants' compound claims meet this requirement and that the Examiner has not considered Applicants' compounds "as a whole" which is expressly required. It is further submitted that the Examiner is confusing the "special technical features" requirement with the "common structure" requirement under Markush Practice. Applicants' compound claims are clearly analogous to Examples 10.38-10.40 of the of the above-noted PCT Guidelines and clearly meet the Unity of Invention standard.


Moreover, MPEP § 803 requires that, for a proper restriction requirement, not only must the inventions be independent or distinct, but also that there would be a serious burden on the Examiner. It is submitted that such a "serious burden" is non-existent if applicants compound claims 1-5 are examined together.

## **CONCLUSION**

For the foregoing reasons, it is submitted that the Examiner erred in adhering to and making final the Restriction Requirement as it applies to claims 1-5, and reversal of this requirement is respectfully requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7909

  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661

Date: *15 February 2007*



# WIPO



PCT/GL/ISPE/1

ORIGINAL: English

DATE: March 11, 2004

WORLD INTELLECTUAL PROPERTY ORGANIZATION

GENEVA



## PATENT COOPERATION TREATY (PCT)

### PCT INTERNATIONAL SEARCH AND PRELIMINARY EXAMINATION GUIDELINES

(Guidelines for the Processing by International Searching and  
Preliminary Examining Authorities of International Applications  
Under the Patent Cooperation Treaty)

*as in force from March 25, 2004*

1. This document contains the text, as in force from March 25, 2004, of the PCT International Search and Preliminary Examination Guidelines, established by the International Bureau of WIPO after consultation with the International Searching and Preliminary Examining Authorities under the PCT with a view, in particular, to implementing the amendments of the PCT Regulations which entered into force on January 1, 2004.
2. The Guidelines apply to the processing of international applications filed on or after January 1, 2004. They supersede the PCT International Search Guidelines, as in force from September 18, 1998 (document PCT/GL/IS/1), and the PCT International Preliminary Examination Guidelines, as in force from October 9, 1998 (document PCT/GL/IPE/1), which were published in Special Issues of the *PCT Gazette* Nos. S-06/1998 and S-07/1998, respectively. The text of the present Guidelines is the same (subject to minor editorial changes) as in the provisional version of this document (document PCT/GL/ISPE/1 Prov.2) which has been applicable, in practice, since January 1, 2004.
3. The text will also be published in Special Issue No. S-02/2004 (dated March 25, 2004) of the *PCT Gazette*.

PCT INTERNATIONAL SEARCH AND  
PRELIMINARY EXAMINATION GUIDELINES  
*(as in force from March 25, 2004)*

TABLE OF CONTENTS

PART I  
INTRODUCTION AND OVERVIEW

	<u>Paragraphs</u>
<b>Chapter 1</b>	
<b>Introduction</b>	<b>1.01 - 1.14</b>
Purpose and Status of These Guidelines	1.01 - 1.04
Arrangement and Terminology of These Guidelines	1.05 - 1.08
Overview of International Application Process	1.09 - 1.12
The International Phase	1.10 - 1.11
The National (or Regional) Phase	1.12
The International Authorities	1.13 - 1.14
<b>Chapter 2</b>	
<b>Overview of the International Search Stage</b>	<b>2.01 - 2.20</b>
Objectives	2.01 - 2.04
Preliminary Matters	2.05 - 2.09
Receipt of Search Copy from Receiving Office	2.05 - 2.07
Acknowledgement and Allocation by the International Searching Authority	2.08 - 2.09
The International Search Process	2.10 - 2.12
Time Limit for Establishing International Search Report	2.13
Transmittal of the International Search Report, Written Opinion, etc.	2.14
Options Open to the Applicant	2.15
Further Processing of the International Search Report and Written Opinion	2.16 - 2.18
Confidential Treatment	2.16
Publication of the Search Report	2.17
Transmission and Making Available of the International Preliminary Report on Patentability When no Demand Is Filed	2.18
Further Responsibilities of the International Searching Authority	2.19
International-Type Searches	2.20
<b>Chapter 3</b>	
<b>Overview of the International Preliminary Examination Stage</b>	<b>3.01 - 3.29</b>
Introduction	3.01 - 3.06
Preliminary Matters	3.07 - 3.15
Filing of Demand	3.07 - 3.08
Checking of Demand and Notification of Receipt	3.09 - 3.12
Commencement of International Preliminary Examination	3.13 - 3.15
The International Preliminary Examination Process	3.16 - 3.21
Basis of the Written Opinion or International Preliminary Examination Report	3.19 - 3.20

Further Consideration	3.21
Nature of the International Preliminary Examination Report	3.22
Time Limit for Establishing the International Preliminary Examination Report	3.23
Transmittal of the International Preliminary Examination Report	3.24
Further Processing of the International Preliminary Examination Report	3.25 - 3.28
Confidential Treatment	3.25
Making Available of the International Preliminary Examination Report	3.26
Transmission of the International Preliminary Examination Report to Elected Offices	3.27
Translation of International Preliminary Examination Report	3.28
Further Responsibilities of the International Preliminary Examining Authority	3.29

## PART II THE INTERNATIONAL APPLICATION

### Chapter 4

<b>Content of the International Application (Other Than the Claims)</b>	<b>4.01 - 4.32</b>
General	4.01
Description	4.02 - 4.27
Technical Field	4.04
Background Art	4.05
Disclosure of Invention	4.06 - 4.07
Brief Description of Drawings	4.08 - 4.09
Best Mode for Carrying Out the Invention	4.10
Structure and Function	4.11
Sufficiency	4.12 - 4.13
Industrial Applicability	4.14
Nucleotide and/or Amino Acid Sequence Listings	4.15
Deposit of Biological Material	4.16 - 4.18
References to Deposited Microorganisms or Other Biological Material as Part of the Description	4.19
Requirements as to the Language of Sheets Containing References to Deposited Microorganisms or Other Biological Material	4.20
General	4.21 - 4.27
Drawings	4.28
Expressions, Etc., Not to Be Used	4.29 - 4.32

### Appendix to Chapter 4

#### Background Art

### Chapter 5

<b>Claims</b>	<b>5.01 - 5.58</b>
General	5.01 - 5.03
Form and Content of Claims	5.04 - 5.11
Kinds of Claim	5.12 - 5.19
Categories	5.12 - 5.14
Independent and Dependent Claims	5.15 - 5.19
Interpretation of Claims	5.20 - 5.28
"Use" Claims	5.21
Preamble	5.22 - 5.23
Open and Closed Claims	5.24

Means Plus Function Claims	5.25
Product by Process Claims	5.26 - 5.27
Product and Apparatus Limitations in Process Claims	5.28
Inconsistency Between Claims and Description	5.29 - 5.30
Clarity	5.31 - 5.41
Clarity of Relative Terms	5.34 - 5.38
Clarity of Other Terms	5.39 - 5.41
Conciseness, Number of Claims	5.42
Support in Description	5.43 - 5.44
Clear and Complete Disclosure of Claimed Invention	5.45 - 5.58
Sufficiency Commensurate with the Claims	5.52 - 5.53
Relationship of Claims to Disclosure	5.54 - 5.58
<b>Appendix to Chapter 5</b>	
Multiple Dependent Claims	
Interpretation of Claims	
Use Claims	
Product by Process Claims	
Conciseness	
<b>Chapter 6</b>	
<b>Priority</b>	<b>6.01 - 6.17</b>
The Right to Priority	6.01 - 6.05
Determining Priority Dates	6.06 - 6.10
Claiming Priority	6.11 - 6.17
<b>Chapter 7</b>	
<b>Classification of International Applications</b>	<b>7.01 - 7.08</b>
Definition	7.01
Definitive Classification of the International Application	7.02 - 7.04
Multiple Classifications	7.03
Classification of Disclosure as Filed	7.04
Amended Classification in the Case of Later Published International Search Report	7.05
Classification When Scope Is Obscure	7.06
Lack of Unity of Invention	7.07
Classification of International Applications Excluded from International Search	7.08
<b>Chapter 8</b>	
<b>Rule 91 – Obvious Errors in Documents</b>	<b>8.01 - 8.10</b>
Transmittal to Another Authority of a Request for Rectification	8.04 - 8.05
Invitation to the Applicant to Request Rectification	8.06
Request for Rectification Submitted to the International Searching Authority	8.07 - 8.08
Request for Rectification Submitted to the International Preliminary Examining Authority	8.09 - 8.10

## PART III

EXAMINER CONSIDERATIONS COMMON TO BOTH THE INTERNATIONAL  
SEARCHING AUTHORITY AND THE INTERNATIONAL PRELIMINARY  
EXAMINING AUTHORITY**Chapter 9****Exclusions from, and Limitations of, International Search and International****Preliminary Examination****9.01 - 9.41**

## Introduction

9.01

## Excluded Subject Matter

9.02 - 9.15

## Scientific and Mathematical Theories

9.05

## Plant or Animal Varieties or Essentially Biological Processes for the

## Production of Plants and Animals, Other Than Microbiological Processes

9.06

## Schemes, Rules or Methods of Doing Business,

## Performing Purely Mental Acts or Playing Games

9.07

## Methods for Treatment of the Human or Animal Body by Surgery or Therapy;

## Diagnostic Methods Practiced on the Human or Animal Body

9.08 - 9.10

## Mere Presentations of Information

9.11 - 9.14

## Computer Programs, to the Extent That the Authority is not Equipped

## to Carry Out Search or Preliminary Examination on Such Programs

9.15

## General Considerations in Assessing the Nature of the Subject Matter

9.16 - 9.18

## Form of Claims

9.16

## Excluded Matter in Only Some Claims

9.17

## Cases of Doubt

9.18

## Extent of Search and Preliminary Examination in Certain Situations

9.19 - 9.39

## Examples Where Search or Preliminary Examination Possible,

## with an Indication in the Written Opinion

9.20 - 9.25

## Examples of Exceptional Situations Where no Search

## at All is Possible for All or Some of the Claims

9.26 - 9.30

## Non Prior-Art Issues

9.31 - 9.32

## Industrial Applicability

9.33

## Informal Clarification

9.34 - 9.35

## Unclear Claims

9.36 - 9.37

## Perpetual Motion

9.38

## Sequence Listings

9.39

## Declaration of Non-Establishment of International Search Report

9.40

## Multiple Dependent Claims

9.41

**Appendix to Chapter 9**

## Excluded Subject Matter Regarding Schemes, Rules or Methods of Doing

## Business, Performing Purely Mental Acts or Playing Games

## Excluded Subject Matter Pertaining to Programs for Computers

**Chapter 10****Unity of Invention****10.01 - 10.78**

## Determination of Unity of Invention

10.01 - 10.10

## Illustrations of Particular Situations

10.11 - 10.19

## Combinations of Different Categories of Claims

10.12 - 10.16

## "Markush Practice"

10.17

## Intermediate and Final Products

10.18 - 10.19

## Examples Concerning Unity of Invention

10.20 - 10.60

## Claims in Different Categories

10.21 - 10.27

Claims in the Same Category	10.28 - 10.37
Markush Practice	10.38 - 10.45
Intermediate/Final Product	10.46 - 10.51
Biotechnological Inventions	10.52 - 10.59
Process at the International Search Stage	10.60 - 10.70
Invitation to Pay Additional Fees	10.60 - 10.63
Search of Additional Inventions Without Payment of Fees	10.64 - 10.65
Protest Procedure	10.66 - 10.70
Process at the International Preliminary Examination Stage	10.71 - 10.78
Protest Procedure	10.78
<b>Chapter 11</b>	
<b>Prior Art</b>	<b>11.01 - 11.26</b>
Prior Art Generally	11.01
Date of Disclosure	11.02
Relevant Date for International Search Report Purposes	11.03
Relevant Date for Written Opinion and International Preliminary Examination Purposes	11.04 - 11.05
Documents Casting Doubt on Priority Claim Made in the International Application	11.06
Documents Not Within the Prior Art Which May Nevertheless Be Relevant	11.07 - 11.11
Later Published Patent Applications (for Purposes of the International Search Report)	11.07
Later Published Patent Applications (for Purposes of International Preliminary Examination)	11.08 - 11.09
Copending Applications, Including Those Filed on the Same Date	11.10
Documents Relevant to Understanding the Invention	11.11
Form of Disclosure	11.12 - 11.22
Availability of Written Disclosures to the Public	11.12
Disclosure on the Internet	11.13 - 11.20
Differences Between Patent and Non-Patent Citations	11.21
Documents Reproducing an Earlier Oral Description	11.22
Difficulty in Establishing Date of a Document	11.23
Relevant Date in Relation to Individual Claims or Parts of Claims	11.24 - 11.26
<b>Chapter 12</b>	
<b>Novelty</b>	<b>12.01 - 12.10</b>
Meaning of Novelty	12.01 - 12.02
Considerations in Determining Novelty	12.03 - 12.10
Methodology	12.03
Inherent or Implicit Disclosure	12.04
Interpretation of Claims	12.05
Combining Documents	12.06
Alternatives	12.07
Generic vs. Specific Disclosures	12.08 - 12.09
Ranges	12.10
<b>Appendix to Chapter 12</b>	
<b>Chapter 13</b>	
<b>Inventive step</b>	<b>13.01 - 13.19</b>
Meaning of Inventive Step	13.01 - 13.02
Considerations in Determining Inventive Step	13.03 - 13.13

What Is "Obvious"?	13.03
Light of Later Knowledge	13.04
Invention as a Whole; Combination of Known or Obvious Elements	13.05 - 13.07
Assessing the Contribution Against the Prior Art	13.08 - 13.10
The "Person Skilled in the Art"	13.11
Combining Teachings	13.12 - 13.13
Examples	13.14
Other considerations	13.15 - 13.19
Ex Post Facto Analysis	13.15
Technical Value, Long-Felt Needs	13.16 - 13.17
Commercial Success	13.18
Dependent Claims	13.19
<b>Appendix to Chapter 13</b>	
Problem-Solution Approach	
Examples in which a single document calls into question the inventive step	
<b>Chapter 14</b>	
<b>Industrial Applicability</b>	<b>14.01 - 14.06</b>
Meaning of Industrial Applicability	14.01 - 14.03
Methodology	14.04 - 14.06
<b>Appendix to Chapter 14</b>	
Utility	
Specific, or Particular, Utility	
Substantial, or Practical "Real World" Utility	
Credible Utility	
Industrial Applicability	
Special Purpose	
Clear and Complete Disclosure	
Possibility of Realizing the Special Purpose	
Date at Which Requirements Must Be Met	

## PART IV THE INTERNATIONAL SEARCH

<b>Chapter 15</b>	
<b>The International Search</b>	<b>15.01 - 15.70</b>
Objective of the International Search	15.01 - 15.07
Non-Written Disclosures	15.05
Geographical Location, Language, Age and Manner of Disclosure	15.06 - 15.07
The Examiner	15.08 - 15.09
Basis of the Search	15.10 - 15.13
Scope of the International Search	15.14 - 15.16
Orientation and Subject of the International Search	15.17 - 15.24
Analysis of the Claims	15.17 - 15.19
Inventions for Which No Fees Have Been Paid	15.20
Full Coverage	15.21
Speculative Claims	15.22
Dependent Claims	15.23 - 15.24
Search of Particular Claim Types and Features	15.25 - 15.28
Combination of Elements	15.27

Different Categories of Claim	15.28
Cases Where No Meaningful Search Is Possible	15.29 - 15.32
Obvious Errors and Matter Contrary to Public Order	15.30 - 15.32
Search Strategy	15.33 - 15.38
Preliminary Steps	15.33
Abstract and Title	15.34
Classification	15.35
Publication Prior to Search	15.36
Search Statement	15.37 - 15.38
Field of Search	15.39 - 15.47
Analogous Fields	15.44 - 15.47
Conducting the Search	15.48 - 15.58
Security of Searching Using the Internet	15.52 - 15.55
No Documents Found	15.56
Stopping Search	15.57
Recording the Search	15.58
Evaluating the Prior Art	15.59 - 15.67
Matters of Doubt Regarding Relevant Prior Art	15.60 - 15.61
Excluded Subject Matter	15.62
Selection of Citations and Identifying Most Relevant Portions	15.63 - 15.67
Procedure After Searching	15.68 - 15.70
Preparation of the International Search Report	15.68
Amended International Search Reports	15.69
Receipt of Misdirected Article 19 Amendments	15.70
<b>Chapter 16</b>	
<b>International Search Report</b>	<b>16.01 - 16.80</b>
General	16.01 - 16.02
Time Limit for Establishing the International Search Report	16.03
Completing the International Search Report	16.04 - 16.05
Matter Not Required by the Form	16.05
Different Types of International Search Reports	16.06
Form and Language of the International Search Report	16.07 - 16.10
International Search Report Form	16.07 - 16.08
Language of Search Report	16.09
Sheets Included in the Pamphlet	16.10
International-Type Search	16.11
Filling Out the Notification of Transmittal of the International Search Report of the Declaration (Form PCT/ISA/220)	16.12 - 16.19
Address for Correspondence	16.12
Applicant's or Agent's File Reference	16.13
International Application Number	16.14
International Filing Date	16.15
Applicant	16.16
Cases Where No, or Limited, Search Report is Established	16.17 - 16.19
Filling Out the International Search Report (Form PCT/ISA/210)	16.20 - 16.78
Earliest Priority Date	16.20
Total Number of Sheets	16.21
"It Is Also Accompanied by a Copy of Each Prior Art Document Cited in This Report" Box	16.22
Basis of the Report	16.23



Nucleotide and/or Amino Acid Sequence Listings and Related Tables	16.24
Restriction of the Subject of the International Search	16.25 - 16.29
Abstract, Title and Figure	16.30 - 16.47
Classification of Subject Matter	16.48
Fields Searched	16.49
Minimum Documentation Searched	16.50
Documentation Searched Other Than Minimum Documentation	16.51
Electronic Database Consulted	16.52 - 16.55
Previous Search	16.56
Documents Considered to Be Relevant	16.57 - 16.58
Citation Category	16.59 - 16.70
Relationship Between Documents and Claims	16.71
Citation of the Documents	16.72 - 16.75
Finalization of the Report	16.76 - 16.78
Copies of References Cited in the International Search Report	16.79 - 16.80

## PART V

## WRITTEN OPINION/INTERNATIONAL PRELIMINARY EXAMINATION REPORT

**Chapter 17****Content of Written Opinions and the International Preliminary Examination**

<b>Report</b>	<b>17.01 - 17.70</b>
Introduction	17.01 - 17.03
Different Types of Opinion and Report	17.04 - 17.08
Written Opinion of the International Searching Authority	17.04 - 17.05
Written Opinion(s) of the International Preliminary Examining Authority	17.06 - 17.07
The International Preliminary Examination Report	17.08
Content of the Opinion or Report	17.09 - 17.53
Overview of Content	17.09
Form of Opinion or Report	17.10
Data	17.11 - 17.12
Box No. I: Basis of the Written Opinion	17.13 - 17.23
Box No. II: Priority	17.25 - 17.28
Box No. III: Non-Establishment of Opinion with Regard to Novelty, Inventive Step and Industrial Applicability	17.29 - 17.35
Box No. IV: Lack of Unity of Invention	17.36 - 17.39
Box No. V: Reasoned Statement Under Rule 66.2(a)(ii) with Regard to Novelty, Inventive Step or Industrial Applicability and Citations	
Supporting Such Statement	17.40 - 17.42
Box No. VI: Certain Documents Cited	17.43 - 17.46
Box No. VII: Certain Defects in the International Application	17.47
Box No. VIII: Certain Observations on the International Application	17.48
Finalization of the Report	17.49
Language of the Written Opinion and the International Preliminary Examination Report	17.50
Form of Objection	17.51 - 17.52
Ensuring Report Is of Maximal Use for Later Stages	17.53
Invitation to Correct or Amend	17.54 - 17.56
Cases Where Partial Written Opinion or No Written Opinion to Be Established	17.57 - 17.64

Excluded Subject Matter	17.58
Lack of Unity of Invention	17.59 - 17.63
Dealing with Major Objections First	17.64
Other Considerations	17.65 - 17.70
Citation of Certain Documents in the International Search Report	17.65
Additional Documents Taken Into Consideration in Certain Cases	17.66
Inconsistencies Between Description and Claims	17.67
Recommending Amendments	17.68
Consideration of Responses to the Written Opinion	17.69 - 17.70

## PART VI

THE INTERNATIONAL PRELIMINARY EXAMINATION STAGE (OTHER THAN THE  
INTERNATIONAL PRELIMINARY REPORT)**Chapter 18**

<b>Preliminary Procedure on Receipt of the Demand</b>	<b>18.01 - 18.18</b>
Use of Facsimile Machine, Telegraph, Teleprinter, Etc.	18.01
Basis for International Preliminary Examination	18.02 - 18.09
Statement Concerning Amendments	18.03 - 18.06
Language for the Purposes of International Preliminary Examination	18.07 - 18.09
Documents, Etc., for the International Preliminary Examining Authority	18.10 - 18.18
Language of the International Application and of the Demand	18.14 - 18.15
Priority Document and Translation Thereof	18.16
Nucleotide and/or Amino Acid Sequence Listings	18.17 - 18.18

**Chapter 19**

<b>Examination Procedure Before The International Preliminary Examining Authority</b>	<b>19.01 - 19.42</b>
General	19.01 - 19.05
Start of, and Time Limit for, International Preliminary Examination	19.06 - 19.10
Start of Examination	19.07
Time Limit for Completing Examination	19.08 - 19.10
First Stage of International Preliminary Examination	19.11 - 19.16
General	19.11 - 19.12
Cases Where No Written Opinion Is Required	19.13 - 19.14
Cases Where a Further Written Opinion May Be Issued	19.15
Claims for Which No International Search Report Has Been Established	19.16
Further Stage of International Preliminary Examination	19.17 - 19.24
Correction of International Preliminary Examination Report	19.25 - 19.26
Matters Applicable Generally to Various Stages of International Preliminary Examination	19.27 - 19.36
Making Amendments: General Considerations	19.27
Rectification of Obvious Errors	19.28 - 19.30
Informal Communication with the Applicant	19.31 - 19.36
Establishment of the International Preliminary Examination Report	19.37 - 19.38
General	19.37 - 19.38
Determination of Time Limits	19.39 - 19.41
Failure of Applicant to Respond Within a Prescribed Time Limit	19.41
Withdrawal of the Demand or All Elections	19.42

**Chapter 20****Amendments**

	<b>20.01 - 20.22</b>
Amendment Prior to the Start of International Preliminary Examination	20.01 - 20.03
Amendment of the Claims Under Article 19	20.01
Amendment Under Article 34	20.02 - 20.03
Making Amendments: General Considerations	20.04 - 20.08
Appraisal of Amendments	20.09
Additional Subject Matter	20.10 - 20.19
Lack of Support	20.20 - 20.21
Amendments to Translated Applications	20.22

**Appendix to Chapter 20****New Matter**

**PART VII**  
**QUALITY**

**Chapter 21****A Common Quality Framework for International Search and Preliminary Examination**

	<b>21.01 - 21.19</b>
Introduction	21.01 - 21.02
Quality Management System	21.03 - 21.09
Resources	21.05
Administration	21.06
Quality Assurance	21.07
Feedback Arrangements	21.08
Communication and Guidance to Users	21.09
Internal Review	21.10 - 21.15
Monitoring and Measuring	21.12 - 21.13
Analysis	21.14
Improvement	21.15
Reporting Arrangements	21.16 - 21.18
Stage 1	21.17
Stage 2	21.18
Future Developments	21.19

**PART VIII**  
**CLERICAL AND ADMINISTRATIVE PROCEDURES**

**Chapter 22****Clerical and Administrative Procedures**

	<b>22.01 - 22.60</b>
Receipt of the Demand	22.01
Determination of Competent International Preliminary Examining Authority and Marking of the Demand	22.02 - 22.05
Identification of the International Application	22.06
Applicant's Entitlement to File a Demand	22.07 - 22.10
Change in the Applicant	22.10
Election of States	22.11
Check of Particulars Affecting the Date of Receipt	22.12 - 22.13
Checking Whether Demand Is Timely Filed	22.14 - 22.15
Establishing the International Preliminary Examining Authority File	22.16 - 22.19

Transmittal of the Demand to the International Bureau	22.20 - 22.23
Certain Defects in the Demand	22.24 - 22.60
Language	22.27
Signature	22.28 - 22.32
Indications Concerning the Applicant	22.33 - 22.34
Indications Concerning the Agent	22.35 - 22.36
Invitation to Correct Defects in the Demand	22.37 - 22.42
Payment and Refund of Fees	22.43 - 22.49
Transfer of Handling Fees to the International Bureau	22.50
Use of Facsimile Machine, Telegraph, Teleprinter, Etc.	22.51 - 22.52
Irregularities in the Mail Service	22.53
Computation of Time Limits	22.54
Amendments Under Article 19	22.55
Response to the Written Opinion	22.56 - 22.58
Transmittal of the International Preliminary Examination Report	22.59
Withdrawal of the Demand or All Elections	22.60

## Chapter 10 Unity of Invention

### Determination of Unity of Invention

*Article 17(3)(a); Rule 13; Section 206*

10.01 An international application should relate to only one invention or, if there is more than one invention, the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept (Rule 13.1). With respect to a group of inventions claimed in an international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" is defined in Rule 13.2 as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art. The determination is made on the contents of the claims as interpreted in light of the description and drawings (if any).

*Rule 13.2; AI Annex B, Part 1(b)*

10.02 Whether or not any particular technical feature makes a "contribution" over the prior art, and therefore constitutes a "special technical feature," is considered with respect to novelty and inventive step. For example, a document discovered in the international search shows that there is a presumption of lack of novelty or inventive step in a main claim, so that there may be no technical relationship left over the prior art among the claimed inventions involving one or more of the same or corresponding special technical features, leaving two or more dependent claims without a single general inventive concept.

*Rule 13.2*

10.03 Lack of unity of invention may be directly evident "*a priori*," that is, before considering the claims in relation to any prior art, or may only become apparent "*a posteriori*," that is, after taking the prior art into consideration. For example, independent claims to A + X, A + Y, X + Y can be said to lack unity *a priori* as there is no subject matter common to all claims. In the case of independent claims to A + X and A + Y, unity of invention is present *a priori* as A is common to both claims. However, if it can be established that A is known, there is lack of unity *a posteriori*, since A (be it a single feature or a group of features) is not a technical feature that defines a contribution over the prior art.

10.04 Although lack of unity of invention should certainly be raised in clear cases, it should neither be raised nor persisted in on the basis of a narrow, literal or academic approach. There should be a broad, practical consideration of the degree of interdependence of the alternatives presented, in relation to the state of the art as revealed by the international search or, in accordance with Article 33(6), by any additional document considered to be relevant. If the common matter of the independent claims is well known and the remaining subject matter of each claim differs from that of the others without there being any unifying novel inventive concept common to all, then clearly there is lack of unity of invention. If, on the other hand, there is a single general inventive concept that appears novel and involves inventive step, then objection of lack of unity does not arise. For determining the action to be taken by the examiner between these two extremes, rigid rules cannot be given and each case is considered on its merits, the benefit of any doubt being given to the applicant.

10.05 From the preceding paragraphs it is clear that the decision with respect to unity of invention rests with the International Searching Authority or the International Preliminary Examining Authority. However, the Authority should not raise objection of lack of unity of invention merely because the inventions claimed are classified in separate classification

groups or merely for the purpose of restricting the international search to certain classification groups.

*AI Annex B, Part 1(c)*

10.06 Unity of invention has to be considered in the first place only in relation to the independent claims in an international application and not the dependent claims. By "dependent" claim is meant a claim which contains all the features of one or more other claims and contains a reference, preferably at the beginning, to the other claim or claims and then states the additional features claimed (Rule 6.4). The examiner should bear in mind that a claim may also contain a reference to another claim even if it is not a dependent claim as defined in Rule 6.4. One example of this is a claim referring to a claim of a different category (for example, "Apparatus for carrying out the process of Claim 1 ...," or "Process for the manufacture of the product of Claim 1 ..."). Similarly, in a situation like the plug and socket example in paragraph 5.19, a claim to the one part referring to the other cooperating part, for example, "plug for cooperation with the socket of Claim 1 ..." is not a dependent claim.

10.07 If the independent claims avoid the prior art and satisfy the requirement of unity of invention, no problem of lack of unity arises in respect of any claims that depend on the independent claims. In particular, it does not matter if a dependent claim itself contains a further invention. For example, suppose claim 1 claims a turbine rotor blade shaped in a specified manner, while claim 2 is for a "turbine rotor blade as claimed in claim 1" and produced from alloy Z. Then no objection under Rule 13 arises either because alloy Z was new and its composition was not obvious and thus the alloy itself already contains the essential features of an independent possibly later patentable invention, or because, although alloy Z was not new, its application in respect of turbine rotor blades was not obvious, and thus represents an independent invention in conjunction with turbine rotor blades. As another example, suppose that the main claim defines a process for the preparation of a product A starting from a product B and the second claim reads: "Process according to claim 1 characterized by producing B by a reaction using the product C." In this case, too, no objection arises under Rule 13.1, whether or not the process for preparation of B from C is novel and inventive, since claim 2 contains all the features of claim 1. The subject matter of claim 2 therefore falls within claim 1. Equally, no problem arises in the case of a genus/species situation where the genus claim avoids the prior art and satisfies the requirement of unity of invention. Moreover, no problem arises in the case of a combination/subcombination situation where the subcombination claim avoids the prior art and satisfies the requirement of unity of invention and the combination claim includes all the features of the subcombination.

10.08 If, however, an independent claim does not avoid the prior art, then the question whether there is still an inventive link between all the claims dependent on that claim needs to be carefully considered. If there is no link remaining, an objection of lack of unity *a posteriori* (that is, arising only after assessment of the prior art) may be raised. Similar considerations apply in the case of a genus/species or combination/subcombination situation. This method for determining whether unity of invention exists is intended to be applied even before the commencement of the international search. Where a search of the prior art is made, an initial determination of unity of invention, based on the assumption that the claims avoid the prior art, may be reconsidered on the basis of the results of the search of the prior art.

10.09 Alternative forms of an invention may be claimed either in a plurality of independent claims, or in a single claim (but see paragraph 5.18). In the latter case, the presence of the independent alternatives may not be immediately apparent. In either case, however, the same criteria are applied in deciding whether or not there is unity of invention, and lack of unity of

invention may then also exist within a single claim. Where the claim contains distinct embodiments that are not linked by a single general inventive concept, the objection as to lack of unity of invention is raised. Rule 13.3 does not prevent an Authority from objecting to alternatives being contained within a single claim on the basis of considerations such as clarity, the conciseness of claims or the claims fee system applicable in that Authority.

10.10 Objection of lack of unity of invention does not normally arise if the combination of a number of individual elements is claimed in a single claim (as opposed to distinct embodiments as discussed in the paragraph immediately above), even if these elements seem unrelated when considered individually (see paragraph 15.27).

### **Illustrations of Particular Situations**

*AI Annex B, Part 1(d)*

10.11 There are three particular situations for which the method for determining unity of invention contained in Rule 13.2 is explained in greater detail:

- (i) combinations of different categories of claims;
- (ii) so-called "Markush practice;" and
- (iii) intermediate and final products.

Principles for the interpretation of the method contained in Rule 13.2, in the context of each of those situations are set out below. It is understood that the principles set out below are, in all instances, interpretations of and not exceptions to the requirements of Rule 13.2.

Examples to assist in understanding the interpretation on the three areas of special concern referred to in the preceding paragraph are set out below.

### *Combinations of Different Categories of Claims*

*AI Annex B, Part 1(e)*

10.12 The method for determining unity of invention under Rule 13 is construed as permitting, in particular, the inclusion of any one of the following combinations of claims of different categories in the same international application:

- (i) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product, or
- (ii) in addition to an independent claim for a given process, an independent claim for an apparatus or means specifically designed for carrying out the said process, or
- (iii) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product and an independent claim for an apparatus or means specifically designed for carrying out the said process.

A process is specially adapted for the manufacture of a product if it inherently results in the product and an apparatus or means is specifically designed for carrying out a process if the contribution over the prior art of the apparatus or means corresponds to the contribution the process makes over the prior art.

10.13 Thus, a process is considered to be specially adapted for the manufacture of a product if the claimed process inherently results in the claimed product with the technical relationship being present between the claimed product and claimed process. The words "specially adapted" are not intended to imply that the product could not also be manufactured by a different process.

10.14 Also an apparatus or means is considered "specifically designed for carrying out" a claimed process if the contribution over the prior art of the apparatus or means corresponds to the contribution the process makes over the prior art. Consequently, it would not be sufficient that the apparatus or means is merely capable of being used in carrying out the claimed process. However, the expression "specifically designed" does not imply that the apparatus or means could not be used for carrying out another process, nor that the process could not be carried out using an alternative apparatus or means.

10.15 More extensive combinations than those set forth in paragraph 10.12 should be looked at carefully to ensure that the requirements of both Rule 13 (unity of invention) and Article 6 (conciseness of claims) are satisfied. (See paragraph 5.42 regarding conciseness of claims.) In particular, while a single set of independent claims according to one of the subparagraphs of paragraph 10.12 is always permissible, it does not require the International Authority to accept a plurality of such sets which could arise by combining the provisions of Rule 13.3 (which provides that the determination of unity of invention be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim), with the provisions set out in paragraph 10.12 (thus resulting in a set under paragraph 10.12 based on each of a number of independent claims in the same category under Rule 13.3 (see paragraphs 5.12 to 5.14)). The proliferation of claims arising from a combined effect of this kind should be accepted only exceptionally. For example, independent claims are permissible for two related articles such as a transmitter and receiver; however, it does not follow that, under paragraph 10.12, an applicant may include also, in the one international application, four additional independent claims: two for a process for the manufacture of the transmitter and the receiver, respectively, and two for use of the transmitter and receiver, respectively.

10.16 A single general inventive concept must link the claims in the various categories and in this connection the wording of paragraph 10.12 should be carefully noted. The link between product and process in subparagraph (i) is that the latter must be "specially adapted for the manufacture of" the former. Similarly, in paragraph 10.12, subparagraph (ii), the apparatus or means claimed must be "specifically designed for" carrying out the process. Likewise, in subparagraph (iii), the process must be "specially adapted for the manufacture of" the product and the apparatus must be "specifically designed for" carrying out the process. In combinations (i) and (iii), the emphasis is on, and the essence of the invention should primarily reside in, the product, whereas in combination (ii) the emphasis is on, and the invention should primarily reside in, the process. (See Examples below.)

*"Markush Practice"*

*AI Annex B, Part 1(f)*

10.17 Rule 13.2 also governs the situation involving a single claim that defines alternatives (chemical or non-chemical), the so-called "Markush practice." In this special situation, the requirement of a technical interrelationship and the same or corresponding special technical features as defined in Rule 13.2, is considered met when the alternatives are of a similar nature.

(a) When the Markush grouping is for alternatives of chemical compounds, they are regarded as being of a similar nature where the following criteria are fulfilled:

- (A) all alternatives have a common property or activity, and
- (B)(1) a common structure is present, that is, a significant structural element is shared by all of the alternatives, or



(B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.

(b) In paragraph (a)(B)(1), above, the words "significant structural element is shared by all of the alternatives" refer to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure constitutes a structurally distinctive portion in view of existing prior art, and the common structure is essential to the common property or activity. The structural element may be a single component or a combination of individual components linked together.

(c) In paragraph (a)(B)(2), above, the words "recognized class of chemical compounds" mean that there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention. In other words, each member could be substituted one for the other, with the expectation that the same intended result would be achieved.

(d) The fact that the alternatives of a Markush grouping can be differently classified is not, taken alone, considered to be justification for a finding of a lack of unity of invention.

(e) When dealing with alternatives, if it can be shown that at least one Markush alternative is not novel over the prior art, the question of unity of invention should be reconsidered by the examiner. Reconsideration does not necessarily imply that an objection of lack of unity will be raised.

(See Examples below.)

#### *Intermediate and Final Products*

*AI Annex B, Part 1(g)*

10.18 Rule 13.2 also governs the situation involving intermediate and final products.

(a) The term "intermediate" is intended to mean intermediate or starting products. Such products have the ability to be used to produce final products through a physical or chemical change in which the intermediate loses its identity.

(b) Unity of invention is considered to be present in the context of intermediate and final products where the following two conditions are fulfilled:

(A) the intermediate and final products have the same essential structural element, in that:

(1) the basic chemical structures of the intermediate and the final products are the same, or

(2) the chemical structures of the two products are technically closely interrelated, the intermediate incorporating an essential structural element into the final product, and

(B) the intermediate and final products are technically interrelated, this meaning that the final product is manufactured directly from the intermediate or is separated from it by a small number of intermediates all containing the same essential structural element.

(c) Unity of invention may also be considered to be present between intermediate and final products of which the structures are not known, for example, as between an intermediate having a known structure and a final product the structure of which is not known, or as

between an intermediate of unknown structure and a final product of unknown structure. In order to satisfy unity in such cases, there must be sufficient evidence to lead one to conclude that the intermediate and final products are technically closely interrelated as, for example, when the intermediate contains the same essential element as the final product or incorporates an essential element into the final product.

(d) It is possible in a single international application to accept different intermediate products used in different processes for the preparation of the final product, provided that they have the same essential structural element.

(e) The intermediate and final products must not be separated, in the process leading from one to the other, by an intermediate that is not new.

(f) If the same international application claims different intermediates for different structural parts of the final product, unity is not regarded as being present between the intermediates.

(g) If the intermediate and final products are families of compounds, each intermediate compound must correspond to a compound claimed in the family of the final products. However, some of the final products may have no corresponding compound in the family of the intermediate products so that the two families need not be absolutely congruent.

*AI Annex B, Part 1(h)*

10.19 As long as unity of invention can be recognized applying the above interpretations, the fact that, besides the ability to be used to produce final products, the intermediates also exhibit other possible effects or activities should not affect the decision on unity of invention.

### **Examples Concerning Unity of Invention**

10.20 The application of the principles of unity of invention is illustrated by the following examples for guidance in particular cases.

#### *Claims in Different Categories*

##### 10.21 *Example 1*

*Claim 1: A method of manufacturing chemical substance X.*

*Claim 2: Substance X.*

*Claim 3: The (method of) use of substance X as an insecticide.*

Unity exists between claims 1, 2 and 3. The special technical feature common to all the claims is substance X. However, if substance X is known in the art, unity would be lacking because there would not be a special technical feature common to all the claims.

##### 10.22 *Example 2*

*Claim 1: A process of manufacture comprising steps A and B.*

*Claim 2: Apparatus specifically designed for carrying out step A.*

*Claim 3: Apparatus specifically designed for carrying out step B.*

Unity exists between claims 1 and 2 or between claims 1 and 3. There is no unity between claims 2 and 3 since there exists no common special technical feature between the two claims.

##### 10.23 *Example 3*

*Claim 1: A process for painting an article in which the paint contains a new rust inhibiting substance X including the steps of atomizing the paint using*

*compressed air, electrostatically charging the atomized paint using a novel electrode arrangement A and directing the paint to the article.*

*Claim 2: A paint containing substance X.*

*Claim 3: An apparatus including electrode arrangement A.*

Unity exists between claims 1 and 2 where the common special technical feature is the paint containing substance X or between claims 1 and 3 where the common special technical feature is the electrode arrangement A. However, unity is lacking between claims 2 and 3 since there exists no common special technical feature between them.

#### 10.24 Example 4

*Claim 1: Use of a family of compounds X as insecticides.*

*Claim 2: Compound X<sub>1</sub> belonging to family X.*

Provided X<sub>1</sub> has the insecticidal activity and the special technical feature in claim 1 is the insecticidal use, unity is present.

#### 10.25 Example 5

*Claim 1: A process for treating textiles comprising spraying the material with a particular coating composition under special conditions (for example, as to temperature, irradiation).*

*Claim 2: A textile material coated according to the process of claim 1.*

*Claim 3: A spraying machine for use in the process of claim 1 and characterized by a new nozzle arrangement providing a better distribution of the composition being sprayed.*

The process according to claim 1 imparts unexpected properties to the product of claim 2. The special technical feature in claim 1 is the use of special process conditions corresponding to what is made necessary by the choice of the particular coating. Unity exists between claims 1 and 2. The spraying machine in claim 3 does not correspond to the above identified special technical feature. Unity does not exist between claim 3 and claims 1 and 2.

#### 10.26 Example 6

*Claim 1: A fuel burner with tangential fuel inlets into a mixing chamber.*

*Claim 2: A process for making a fuel burner including the step of forming tangential fuel inlets into a mixing chamber.*

*Claim 3: A process for making a fuel burner including casting step A.*

*Claim 4: An apparatus for carrying out a process for making a fuel burner including feature X resulting in the formation of tangential fuel inlets.*

*Claim 5: An apparatus for carrying out a process for making a fuel burner including a protective housing B.*

*Claim 6: A process of manufacturing carbon black including the step of tangentially introducing fuel into a mixing chamber of a fuel burner.*

Unity exists between claims 1, 2, 4, and 6. The special technical feature common to all the claims is the tangential fuel inlets. Claims 3 and 5 lack unity with claims 1, 2, 4, and 6 since claims 3 and 5 do not include the same or corresponding special technical feature as set forth in claims 1, 2, 4, and 6. Claims 3 and 5 would also lack unity with one another.

10.27 *Example 7*

*Claim 1: A high corrosion resistant and high strength ferritic stainless steel strip consisting essentially of, in percent by weight: Ni=2.0-5.0; Cr=15-19; Mo=1-2; and the balance Fe, having a thickness of between 0.5 and 2.0 mm and a 0.2% yield strength in excess of 50 kg/mm squared.*

*Claim 2: A method of producing a high corrosion resistant and high strength ferritic stainless steel strip consisting essentially of, in percent by weight: Ni=2.0-5.0; Cr=15-19; Mo=1-2; and the balance Fe, comprising the steps of:*

- (a) hot rolling to a thickness between 2.0 and 5.0 mm;*
- (b) annealing the hot rolled strip at 800-1000°C under substantially no oxidizing conditions;*
- (c) cold rolling the strip to a thickness of between 0.5 and 2.0 mm; and*
- (d) final annealing the cold rolled strip at between 1120 and 1200°C for a period of 2-5 minutes.*

Unity exists between product claim 1 and process claim 2. The special technical feature in the product claim is the 0.2% yield strength in excess of 50 kg/mm squared. The process steps in claim 2 inherently produce a ferritic stainless steel strip with a 0.2% yield strength in excess of 50 kg/mm squared. Even if this feature is not apparent from the wording of claim 2, it is clearly disclosed in the description. Therefore said process steps are the special technical feature which correspond to the limitation in the product claim directed to the same ferritic stainless steel with the claimed strength characteristics.

*Claims in the Same Category*10.28 *Example 8*

*Claim 1: Plug characterized by feature A.*

*Claim 2: Socket characterized by corresponding feature A.*

Feature A is a special technical feature that is included in both claims 1 and 2 and therefore unity is present.

10.29 *Example 9*

*Claim 1: Transmitter provided with time axis expander for video signals.*

*Claim 2: Receiver provided with time axis compressor for video signals received.*

*Claim 3: Transmission equipment for video signals comprising a transmitter provided with time axis expander for video signals and a receiver provided with time axis compressor for video signals received.*

The special technical features are, in claim 1 the time axis expander, and in claim 2 the time axis compressor, which are corresponding technical features. Unity exists between claims 1 and 2. Claim 3 includes both special technical features and has unity with claims 1 and 2. The requirement for unity would still be met in the absence of the combination claim (claim 3).

10.30 *Example 10*

*Claim 1: Conveyor belt with feature A.*

*Claim 2: Conveyor belt with feature B.*

*Claim 3: Conveyor belt with features A + B.*

*Feature A is a special technical feature and feature B is another unrelated special technical feature.*

Unity exists between claims 1 and 3 or between claims 2 and 3, but not between claims 1 and 2.

#### 10.31 Example 11

*Claim 1: Control circuit A for a d.c. motor.*

*Claim 2: Control circuit B for a d.c. motor.*

*Claim 3: An apparatus including a d.c. motor with control circuit A.*

*Claim 4: An apparatus including a d.c. motor with control circuit B.*

*Control circuit A is a special technical feature and control circuit B is another unrelated special technical feature.*

Unity exists between claims 1 and 3 or between claims 2 and 4, but not between claims 1 and 2 or 3 and 4.

#### 10.32 Example 12

*Claim 1: A display with features A + B.*

*Claim 2: A display according to claim 1 with additional feature C.*

*Claim 3: A display with features A + B with additional feature D.*

Unity exists between claims 1, 2, and 3. The special technical feature common to all the claims is features A + B.

#### 10.33 Example 13

*Claim 1: Filament A for a lamp.*

*Claim 2: Lamp B having filament A.*

*Claim 3: Searchlight provided with lamp B having filament A and a swivel arrangement C.*

Unity exists between claims 1, 2, and 3. The special technical feature common to all the claims is the filament A.

#### 10.34 Example 14

*Claim 1: A marking device for marking animals, comprising a disc-shaped element with a stem extending normally therefrom, the tip of which is designed to be driven through the skin of the animal to be marked, and a securing disc element to be fastened to the protruding tip of the stem on the other side of skin.*

*Claim 2: An apparatus for applying the marking device of claim 1, constructed as a pneumatically actuated gun for driving the stem of the disc-shaped element through the skin, and provided with a supporting surface adapted for taking up a securing disc element, to be placed at the other side of the body portion in question of the animal to be marked.*

The special technical feature in claim 1 is the marking device having a disc-shaped element with a stem and a securing disc element to be fastened to the tip of the stem. The corresponding special technical feature in claim 2 is the pneumatically actuated gun for

driving the marking device and having a supporting surface for the securing disc element.  
Unity exists between claims 1 and 2.

#### 10.35 Example 15

*Claim 1: Compound A.*

*Claim 2: An insecticide composition comprising compound A and a carrier.*

Unity exists between claims 1 and 2. The special technical feature common to all the claims is compound A.

#### 10.36 Example 16

*Claim 1: An insecticide composition comprising compound A (consisting of  $a_1$ ,  $a_2$ ...) and a carrier.*

*Claim 2: Compound  $a_1$ .*

*All compounds A are not claimed in the product claim 2 for reasons of lack of novelty of some of them for instance.*

There is nevertheless still unity between the subject matter of claims 1 and 2 provided  $a_1$  has the insecticidal activity that is also the special technical feature for compound A in claim 1.

#### 10.37 Example 17

*Claim 1: A chair with a lifting mechanism.*

*Claim 2: A chair with a mechanical screw lifting mechanism.*


*Claim 3: A chair with a hydraulic lifting mechanism.*

Unity exists between claims 1-3. The special technical feature common to all the claims is the lifting mechanism. However, if any lifting mechanism is known in the art, unity would be lacking because there would not be a special technical feature common to all the claims.

#### Markush Practice

#### 10.38 Example 18: Common Structure

*Claim 1: A compound of the formula:*




*wherein  $R^1$  is selected from the group consisting of phenyl, pyridyl, thiazolyl, triazinyl, alkylthio, alkoxy, and methyl;  $R^2$ - $R^4$  are methyl, benzyl, or phenyl. The compounds are useful as pharmaceuticals for the purpose of enhancing the capacity of the blood to absorb oxygen.*

In this case the indolyl moiety is the significant structural element that is shared by all of the alternatives. Since all the claimed compounds are alleged to possess the same utility, unity is present.

## 10.39 Example 19: common structure:

Claim 1: A compound of the formula:




wherein  $R_1$  is selected from the group consisting of phenyl, pyridyl, thiazolyl, triazinyl, alkylthio, alkoxy, and methyl;  $Z$  is selected from the group consisting of oxygen (O), sulfur (S), imino (NH), and methylene ( $-CH_2-$ ).

The compounds are alleged to be useful as pharmaceuticals for relieving lower back pain.

In this particular case the iminothioether group  $-N=C-SCH_3$  linked to a six atom ring is the significant structural element which is shared by all the alternatives. Thus, since all the claimed compounds are alleged to possess the same use, unity would be present.

## 10.40 Example 20: Common Structure

Claim 1: A compound of the formula:




wherein  $R'$  is methyl or phenyl,  $X$  and  $Z$  are selected from oxygen (O) and sulfur (S).

The compounds are useful as pharmaceuticals and contain the 1,3-thiazolyl substituent which provides greater penetrability of mammalian tissue which makes the compounds useful as relievers for headaches and as topical anti-inflammatory agents.


All compounds share a common chemical structure, the thiazole ring and the six atom heterocyclic compound bound to an imino group, which occupy a large portion of their structure. Thus, since all the claimed compounds are alleged to possess the same use, unity would be present.

## 10.41 Example 21: Common Structure



$$1 \leq l \leq 10$$



$$200 \geq n + m \geq 100$$



*All of the above copolymers have in common a thermal degradation resistance property, due to the reduced number of free COOH radicals by esterification with X of the end COOH radicals which cause thermal degradation.*

The chemical structures of the alternatives are considered to be technically closely interrelated to one another. A grouping in one claim is therefore allowed.

10.42 Example 22: Common Structure:



*The compound obtained by esterifying the end COOH radical of known polyhexamethyleneterephthalate with  $\text{H}-\text{CH}_2\text{O}-$  has a thermal degradation resistant property, due to the reduced number of free COOH radicals which cause thermal degradation. In contrast, the compound obtained by esterifying the end COOH radical of known polyhexamethyleneterephthalate with a vinyl compound containing a  $\text{CH}_2=\text{CH}-\text{C}_6\text{H}_4-\text{CH}_2\text{O}-$  moiety serves as a raw material for a setting resin when mixed with unsaturated monomer and cured (addition reaction).*

All esters covered by the claim do not have a property or activity in common. For example, the product obtained through esterification with the " $\text{CH}_2=\text{CH}$ " vinyl compound does not have a thermal degradation resistant property. The grouping in a single application is not allowed.

10.43 Example 23: No Common Structure

*Claim 1: A herbicidal composition consisting essentially of an effective amount of the mixture of A 2,4-D(2,4-dichloro-phenoxy acetic acid) and B a second herbicide selected from the group consisting of copper sulfate, sodium chlorate, ammonium sulfamate, sodium trichloroacetate, dichloropropionic acid, 3-amino-2,5-dichlorobenzoic acid, diphenamid (an amide), ioxynil (nitrile), dinoseb (phenol), trifluralin (dinitroaniline), EPTC (thiocarbamate), and simazine (triazine) along with an inert carrier or diluent.*

The different components under B must be members of a recognized class of compounds. Consequently in the present case a unity objection would be raised because the members of B are not recognized as a class of compounds, but, in fact, represent a plurality of classes which may be identified as follows:

(a) inorganic salts:

copper sulfate  
sodium chlorate  
ammonium sulfamate

(b) organic salts and carboxylic acids:

sodium trichloroacetate



dichloropropionic acid

3-amino-2,5-dichlorobenzoic acid

(c) amides:

diphenamid

(d) nitriles:

ioxynil

(e) phenols:

dinoseb

(f) amines:

trifluralin

(g) heterocyclic:

simazine

#### 10.44 Example 24

*Claim 1: A pharmaceutical compound of the formula:*



*wherein:*

*A is selected from C<sub>1</sub>-C<sub>10</sub> alkyl or alkenyl or cycloalkyl, substituted or unsubstituted aryl or C<sub>5</sub>-C<sub>7</sub> heterocycle having 1-3 heteroatoms selected from O and N;*

*B is selected from C<sub>1</sub>-C<sub>6</sub> alkyl or alkenyl or alkynyl, amino, sulfoxy, C<sub>3</sub>-C<sub>8</sub> ether or thioether;*

*C is selected from C<sub>5</sub>-C<sub>8</sub> saturated or unsaturated heterocycle having 1-4 heteroatoms selected from O, S or N or is a substituted or unsubstituted phenyl;*

*D is selected from B or a C<sub>4</sub>-C<sub>8</sub> carboxylic acid ester or amide; and*

*E is selected from substituted or unsubstituted phenyl, naphthyl, indolyl, pyridyl, or oxazolyl.*

From the above formula no significant structural element can be readily ascertained and thus no special technical feature can be determined. Lack of unity exists between all of the various combinations. The first claimed invention would be considered to encompass the first mentioned structure for each variable, that is, A is C<sub>1</sub> alkyl, B is C<sub>1</sub> alkyl, C is a C<sub>5</sub> saturated heterocycle having one O heteroatom, D is C<sub>1</sub> alkyl, and E is a substituted phenyl.

#### 10.45 Example 25

*Claim 1: Catalyst for vapor phase oxidation of hydrocarbons, which consists of (X) or (X+a).*

*In this example (X) oxidizes RCH<sub>3</sub> into RCH<sub>2</sub>OH and (X+a) oxidizes RCH<sub>3</sub> further into RCOOH.*


*Both catalysts share a common component and a common activity as oxidation catalyst for RCH<sub>3</sub>. With (X+a) the oxidation is more complete and goes until the carboxylic acid is formed but the activity still remains the same.*

A Markush grouping is acceptable in this case.

*Intermediate/Final Product*


10.46 Example 26

*Claim 1:*




*(intermediate)*

*Claim 2:*



*(final product)*


*The chemical structures of the intermediate and final product are technically closely interrelated. The essential structural element incorporated into the final product is:*



Therefore, unity exists between claims 1 and 2.


## 10.47 Example 27

Claim 1:



(I)

Claim 2:



(II)

(II) is described as an intermediate to make (I). The closure mechanism is one well known in the art. Though the basic structures of compound (I) (final product) and compound (II) (intermediate) differ considerably, compound (II) is an open ring precursor to compound (I). Both compounds share a common essential structural element that is the linkage comprising the two phenyl rings and the triazole ring. The chemical structures of the two compounds are therefore considered to be technically closely interrelated.

The example therefore satisfies the requirement for unity of invention.

## 10.48 Example 28

Claim 1: Amorphous polymer A (intermediate).

Claim 2: Crystalline polymer A (final product).


In this example a film of the amorphous polymer A is stretched to make it crystalline.

Here unity exists because there is an intermediate final product relation in that amorphous polymer A is used as a starting product to prepare crystalline polymer A.


For purposes of further illustration, assume that the polymer A in this example is polyisoprene. Here the intermediate, amorphous polyisoprene, and the final product, crystalline polyisoprene, have the same chemical structure.

## 10.49 Example 29

*Claim 1: Polymeric compound useful as fiber material identified by the following general formula:*



*Claim 2: Compound identified by the following general formula:  
(useful as intermediate for polymeric compound I)*



*The two inventions are in an intermediate and final product relationship.*

*Substance (II) is a raw material for substance (I).*

Meanwhile, both compounds share an essential structural element (repeating unit (X)) and are technically closely interrelated. The intermediate and final products therefore satisfy the requirements for unity.

## 10.50 Example 30

*Claim 1: Novel compound having structure A (Intermediate).*

*Claim 2: Product prepared by reacting A with a substance X (Final Product).*

*(see below for further details)*

## 10.51 Example 31

*Claim 1: Reaction product of A and B (Intermediate).*

*Claim 2: Product prepared by reacting the reaction product of A and B with substances X and Y (Final Product).*

*In examples 30 and 31 the chemical structure(s) of the intermediate and/or the final product is not known. In (30) the structure of the product of claim 2 (the final product) is not known. In (31) the structures of the products of claim 1 (the intermediate) and claim 2 (the final product) are unknown.*

Unity exists if there is evidence that would lead one to conclude that the characteristic of the final product which is the inventive feature in the case is due to the intermediate. For example, the purpose for using the intermediates in Examples 30 or 31 is to modify certain properties of the final product. The evidence may be in the form of test data in the

specification showing the effect of the intermediate on the final product. If no such evidence exists then there is no unity on the basis of an intermediate-final product relationship.

### *Biotechnological Inventions*

#### 10.52 *Example 32: Multiple Structurally and Functionally Unrelated Polynucleotides*

*Claim 1: An isolated polynucleotide selected from the group consisting of the nucleotide sequences SEQ ID NOs: 1-10.*

*(Some Authorities presume that a claimed biological molecule is in isolated form and therefore do not require the claim to explicitly include the term "isolated" as above.)*

*The description discloses that the claimed polynucleotides are 500 bp cDNAs obtained from a human liver cDNA library. The polynucleotides are structurally different and can be used as probes to obtain full-length DNAs, although there is no description of the function or biological activity of the corresponding proteins. Furthermore, the polynucleotides claimed are not homologous to each other.*

*There is no prior art available. A human liver cDNA library had not been established before.*

The polynucleotides of claim 1 would be regarded as having the same or corresponding technical feature if the alternatives had a common property or activity, and shared a significant structural element that is essential to the common property or activity. Some Offices may regard claim 1 as a Markush grouping.

In this example, the description fails to disclose that all of the polynucleotides SEQ ID NOs: 1-10 share a common property or activity. While each sequence may serve as a probe to isolate its own respective full length DNA, due to the lack of homology between SEQ ID NOs: 1-10, a probe derived from SEQ ID NO: 1 cannot be used to isolate SEQ ID NOs: 2-10, respectively.

Moreover, since the polynucleotides are not homologous to each other, they fail to share a common structure i.e., a significant structural element. The sugar-phosphate backbone cannot be considered a significant structural element, since it is shared by all nucleic acid molecules. Therefore, the 10 polynucleotide molecules do not share any significant structural element and cannot be considered as having the same or corresponding technical feature.

The mere fact that polynucleotide fragments are derived from the same source (human liver) is not sufficient to meet the criteria for unity of invention. The polynucleotides fail to share a common property or activity and fail to share a common structure. Since neither of these two requirements is met, the group of polynucleotide molecules claimed does not meet the requirement of unity of invention (*a priori*).

One possible grouping would be:

Inventions 1-10: Polynucleotides having SEQ ID NOs: 1-10.

#### 10.53 *Example 33: Multiple Structurally and Functionally Related Polynucleotides*

*Claim 1: An isolated polynucleotide selected from the group consisting of the nucleotide sequences SEQ ID NOs: 1-10.*

*(Some Authorities presume that a claimed biological molecule is in isolated form and therefore do not require the claim to explicitly include the term "isolated" as above.)*

*The facts are the same as Example 32 except that the claimed polynucleotides all share a significant structural element and their corresponding mRNAs are expressed only in*

*the hepatocytes of patients with disease Y. The corresponding mRNAs are not expressed in the hepatocytes of healthy individuals.*

*There is no prior art available. The shared structural element had not been identified before, nor had any link been established between genes expressing mRNA containing that structural element and patients afflicted with disease Y.*

The polynucleotides of claim 1 would be regarded as having the same or corresponding technical feature if the alternatives had a common property or activity, and shared a significant structural element that is essential to the common property or activity. Some Offices may regard claim 1 as a Markush grouping.

In this example, the description discloses that SEQ ID NOs: 1-10 share a common property, that is, expression of an mRNA present only in patients afflicted with disease Y. Moreover, SEQ ID NOs: 1-10 share a significant structural element that is essential to the common property, i.e., a probe comprising the shared structural element can detect the mRNA of patients afflicted with disease Y. Since both of these requirements are met, the group of polynucleotide molecules claimed meets the requirement of unity of invention (*a priori*).

#### 10.54 Example 34: Functionally Unrelated Single Nucleotide Polymorphisms (SNPs)

*Claim 1: An isolated nucleic acid molecule comprising SEQ ID NO: 1 with a single polymorphic change at one of the positions as shown below:*

<i>Polymorphism</i>	<i>Position</i>	<i>Change from SEQ ID NO: 1 to:</i>
1	10	G
2	27	A
3	157	C
4	234	T
5	1528	G
6	3498	C
7	13524	T
8	14692	A

*(Some Authorities presume that a claimed biological molecule is in isolated form and therefore do not require the claim to explicitly include the term "isolated" as above.)*

*According to the description, SEQ ID NO: 1 is 22,930 nucleotides in length. The SNPs 1-8 are not characterized, that is, no common property or activity has been disclosed.*

*SEQ ID NO: 1 has been described in the prior art but no specific function has been identified.*

The polynucleotides of claim 1 would be regarded as having the same or corresponding technical feature if the alternatives had a common property or activity, and shared a significant structural element that is essential to the common property or activity. Some Offices may regard claim 1 as a Markush grouping.

In this example, the description fails to disclose that all of the SNPs 1-8 share a common property or activity. The fact that all point mutations are within a defined sequence (SEQ ID NO: 1) is not sufficient to establish unity of invention since SEQ ID NO: 1 has already been described in the prior art, and no functional relationship exists among the different SNPs claimed. For this reason, the SNPs of claim 1 lack unity of invention.

One possible grouping would be:

Inventions 1-8: SNPs 1-8.

**10.55 Example 35: Molecules Which Share a Common Function not Linked to a Common Structure**

*Claim 1: A fusion protein comprising carrier protein X linked to a polypeptide having SEQ ID NO 1, 2, or 3.*

*The description discloses that carrier protein X is 1000 amino acids in length and functions to increase the stability of the fusion proteins in the blood stream. SEQ ID NOs: 1, 2, and 3 are small epitopes (10-20 residues in length) isolated from different antigenic regions of E.coli. SEQ ID NOs: 1, 2, and 3 do not share any significant common structure.*

*Both the structure of protein X and its function as a carrier protein are known in the prior art. Fusion proteins that generate an antigenic response to E. coli are known in the prior art.*

The fusion proteins of claim 1 would be regarded as having the same or corresponding technical feature if the alternatives had a common property or activity, and shared a significant structural element that is essential to the common property or activity. Some Offices may regard claim 1 as a Markush grouping.

In this example, the only common structure shared by the fusion proteins is carrier protein X. The fusion proteins share a common property, i.e., generation of an antibody response specific for *E. coli*. However, immunization with the carrier protein alone does not result in the common property; SEQ ID NO: 1, 2, or 3 is required for this property.

No special technical feature exists among the three fusion proteins. The fact that all the fusion proteins have a common property is not sufficient to establish unity of invention because (1) SEQ ID NOs: 1, 2, and 3, which impart the common property, do not share a significant structural element, (2) the common structure, carrier protein X, does not impart the common property, and (3) fusion proteins that generate an antigenic response specific for *E. coli* are known in the prior art.

One possible grouping would be:

Invention 1: Fusion protein comprising carrier protein X and SEQ ID NO: 1.

Invention 2: Fusion protein comprising carrier protein X and SEQ ID NO: 2.

Invention 3: Fusion protein comprising carrier protein X and SEQ ID NO: 3.

**10.56 Example 36: Multiple Nucleic Acid Molecules Which Share Common Structure and Encode Proteins with Common Property**

*Claim 1: An isolated nucleic acid selected from SEQ ID NO: 1, 2, or 3.*

*(Some Authorities presume that a claimed biological molecule is in isolated form and therefore do not require the claim to explicitly include the term "isolated" as above.)*

*The description discloses that the three nucleic acids encode dehydrogenases that include a conserved sequence motif defining the catalytic site and the dehydrogenase function of these proteins. The three nucleic acids were isolated from three different sources (mouse, rat, and human). The description clearly shows that these three nucleic acids are homologous based upon their overall sequence similarity (85-95% identity) at both the nucleotide and amino acid sequence levels.*

*The prior art describes a nucleic acid molecule isolated from monkeys, which has high sequence similarity (e.g., 90%) to SEQ ID NO: 1. The monkey nucleic acid encodes a dehydrogenase that includes the catalytic site defined by the conserved motif.*

The nucleic acids of claim 1 would be regarded as having the same or corresponding technical feature if the alternatives had a common property or activity, and shared a significant structural element that is essential to the common property or activity. Some Offices may regard claim 1 as a Markush grouping.

Rule 13.2 requires that the technical feature shared between the inventions defines a contribution over the prior art.

A same or corresponding technical feature shared among the claimed nucleic acid molecules resides in their common property (encoding dehydrogenases) and their shared structural element that is essential to the common property (the conserved motif). However, a nucleic acid molecule which encodes a dehydrogenase and contains the shared structural element has already been isolated from a different source (monkeys). Thus, the technical feature is not special because the functional and structural similarity between the claimed molecules cannot form the contribution that the group of inventions as a whole makes over the prior art. Therefore, unity of invention is lacking (*a posteriori*).

On the other hand, if the only prior art available disclosed a nucleic acid molecule encoding a dehydrogenase that lacked the catalytic site defined by the conserved sequence motif, the technical feature would be special and SEQ ID NOs: 1, 2, and 3 would have unity of invention.

A possible grouping would be:

Invention 1: Nucleic acid of SEQ ID NO: 1

Invention 2: Nucleic acid of SEQ ID NO: 2

Invention 3: Nucleic acid of SEQ ID NO: 3

**10.57 Example 37: DNA Encoding Receptors with Partial Structural Identity and Asserted Common Property**

*Claim 1: A polynucleotide encoding a guanosine triphosphate-binding protein coupled receptor (GPCR) comprising a nucleotide sequence selected from the group consisting of the odd-numbered SEQ ID NOs from SEQ ID NO: 1 to SEQ ID NO: 2069.*

*The description identifies a conserved sequence of 15 amino acid residues found in several known GPCR molecules that is asserted to be essential to the GPCR function. A consensus polynucleotide sequence encoding the conserved amino acid sequence was generated. A database containing human genome sequences was searched using the consensus polynucleotide sequence. Using this system, 1035 polynucleotide sequences were identified, which are asserted to encode GPCR molecules that include the conserved sequence.*

*The prior art discloses human GPCR molecules that contain the conserved sequence of 15 amino acid residues, as well as the polynucleotide sequences that encode the conserved 15 amino acid sequence.*

The common technical feature among the 1035 polynucleotide sequences is the consensus polynucleotide sequence that encodes the common sequence of 15 amino acid residues. This technical feature is not special because the consensus polynucleotide sequence was known and therefore cannot form the contribution that the group of inventions as a whole makes over



the prior art. Consequently, the 1035 different polynucleotides lack unity of invention (*a posteriori*).

One possible grouping would be:

Inventions 1-1035: Polynucleotides based on SEQ ID NOs: 1-2070 (odd-numbers)

If the description did not assert, or it was not readily apparent, that the conserved sequence of 15 amino acid residues was essential to the GPCR function, unity of invention could be lacking in the absence of any relevant prior art.

On the other hand, given the assertion in the description, in the absence of the prior art in the example, the groups would have had unity of invention.

10.58 *Example 38: Method of Screening and Compounds Identified by the Method*

*Claim 1: A method to identify compounds that are antagonists of receptor R comprising the steps of contacting cells expressing on their outer membrane receptor R with its natural ligand; observing the binding of the ligand; contacting said cells bound to said ligand with a candidate compound selected from a library of compounds; and observing any change in the binding of the ligand.*

*Claim 2: Compound X, having formula 1.*

*Claim 3: Compound Y, having formula 2.*

*Claim 4: Compound Z, having formula 3.*

*Receptor R and its natural ligand are proposed as a drug target. Compounds that antagonise receptor R are proposed to have physiological effects that may be useful in therapeutic treatment. The aim is to identify lead compounds as a basis for further screening and testing of combinatorial libraries. A library is described as providing many possible structurally different compounds. Examples show that the method of claim 1 can be used to identify compounds affecting the physiological effect of binding of the natural ligand to the receptor. Only compounds X, Y and Z were shown to have such effects, but they do not appear to share a significant structural element. The description is silent with regard to the both the relationship between the structure and activity of the claimed compounds and the relationship between the structure of receptor R and the structure of the compounds.*

*Receptor R, its biological function, and its natural ligand are known in the prior art. No compounds that function as antagonists of receptor R are known.*

The technical feature of method claim 1 resides in the step of observing the effect of the candidate compounds on ligand binding in a screening assay. Neither the same nor a corresponding special technical feature is present in any of compounds X, Y, or Z. No manufacturing relationship exists between the screening method and the claimed compounds. Further, the screening method is not a method of using claimed compounds X, Y, and Z. In the absence of any teaching as to the structure required for a compound to act as a receptor R antagonist, there is no single general concept that links the method to the claimed compounds. Thus, unity of invention is lacking (*a priori*).

Compounds X, Y, and Z would be regarded as having the same or corresponding technical feature if they had a common property or activity, and shared a significant structural element that is essential to the common property or activity. While compounds X, Y, and Z do share the common property of antagonising receptor R, there is no teaching as to a shared significant structural element, and hence, there is no disclosure of the same or corresponding technical feature.

One possible grouping would be:

Invention 1: Method to identify compounds... (claim 1)

Invention 2: Compound X (claim 2)

Invention 3: Compound Y (claim 3)

Invention 4: Compound Z (claim 4)

#### 10.59 Example 39: Protein and its Encoding DNA

*Claim 1: Isolated protein X having SEQ ID NO: 1.*

*Claim 2: Isolated DNA molecule encoding protein X of claim 1.*

*(Some Authorities presume that a claimed biological molecule is in isolated form and therefore do not require the claim to explicitly include the term "isolated" as above.)*

*The disclosure teaches that protein X is an interleukin-1, a soluble cytokine involved in the activation of lymphocytes. The disclosure also sets forth a DNA molecule having SEQ ID NO: 2 that encodes SEQ ID NO: 1.*

*There is no prior art.*

The claimed DNA molecule encodes protein X, and therefore protein X and the DNA encoding protein X share a corresponding technical feature. Consequently, the claims have unity of invention (*a priori*).

Because protein X makes a contribution over the prior art, protein X and the DNA encoding protein X share a special technical feature.

If an alternative DNA claim was presented that encompassed a DNA molecule that did not encode protein X, some Authorities might find that the claims did not share the same or corresponding technical feature and therefore lacked unity. Examples of such a claim follow:

*Isolated DNA molecule encoding protein X, or a DNA fragment thereof.*

*Isolated DNA molecule having SEQ ID NO: 2, or DNA molecules which hybridise to SEQ ID NO: 2 under stringent conditions.*

If prior art existed teaching either protein X or the DNA encoding protein X, some Authorities might find that the same or corresponding technical feature did not make a contribution over the prior art, that is, was not a special technical feature, and therefore unity was lacking (*a posteriori*).

#### Process at the International Search Stage

##### *Invitation to Pay Additional Fees*

*Article 17(3)(a); Rules 16, 40.2, 40.3, 42*

10.60 After deciding that lack of unity exists, except in the circumstances described in paragraphs 10.64 and 10.65, the International Searching Authority informs the applicant of the lack of unity of invention by a communication, preceding (but see paragraph 10.61, below) the issuance of the international search report and written opinion of the International Searching Authority, which contains an invitation to pay additional fees (Form PCT/ISA/206). This invitation specifies the reasons (see paragraph 10.63) for which the international application is not considered as complying with the requirement of unity of invention, identifies the separate inventions and indicates the number of additional search fees and the amount to be paid. The International Searching Authority cannot consider the application withdrawn for lack of unity of invention, nor invite the applicant to amend the

claims, but informs the applicant that, if the international search report is to be drawn up in respect of those inventions present other than the first mentioned, then the additional fees must be paid within a stipulated period.

10.61 If preferred, the said invitation may be already accompanied by a notification of the result of a partial international search drawn up for those parts of the international application which relate to what is to be considered as the "first" invention. The result of the partial international search will be very useful for the applicant in deciding whether additional search fees should be paid so that further parts of the international application would be subjected to the international search. The invention(s) or group(s) of inventions, other than the one first mentioned in the claims, will be searched, subject to paragraphs 10.64 and 10.65, only if the applicant pays the additional fees. Thus, whether the lack of unity of invention is directly evident *a priori* or becomes apparent *a posteriori*, the examiner, may proceed in one of two ways: he may immediately inform the applicant of his finding and invite him to pay additional search fees (with Form PCT/ISA/206) and search or continue to search the invention first mentioned in the claims ("main invention"); or alternatively, he may carry out the search on the "main invention" and draw up a partial international search report which will be sent together with the invitation to pay additional search fees (with Form PCT/ISA/206).

10.62 Since these payments must take place within a period to be set by the International Searching Authority so as to enable the observation of the time limit for establishing the international search report set by Rule 42, the International Searching Authority should endeavor to ensure that international searches be made as early as possible after the receipt of the search copy. The International Searching Authority finally draws up the international search report and written opinion on those parts of the international application which relate to inventions in respect of which the search fee and any additional search fee have been paid. The international search report (see paragraph 16.29) and written opinion (see paragraphs 17.36 and 17.37) identify the separate inventions or groups of inventions forming unity and indicate those parts of the international application for which a search has been made. If no additional search fee has been paid, the international search report and written opinion contain only the references relating to the invention first mentioned in the claims.

*Rule 40.1*

10.63 In the invitation to pay additional fees, the International Searching Authority sets out a logically presented, technical reasoning containing the basic considerations behind the finding of lack of unity.

*Search of Additional Inventions Without Payment of Fees*

10.64 If little or no additional search effort is required, reasons of economy *may* make it advisable for the examiner, while making the search for the main invention, to search at the same time, despite the nonpayment of additional fees, one or more additional inventions in the classification units consulted for the main invention. The international search for such additional inventions will then have to be completed in any further classification units which may be relevant, when the additional search fees have been paid. This situation may occur when the lack of unity of invention is found either *a priori* or *a posteriori*.

10.65 When the examiner finds lack of unity of invention, normally, the applicant is invited to pay fees for the search of additional inventions. In exceptional circumstances, however, the examiner may be able to establish both an international search and a written opinion covering more than one invention with negligible additional work, in particular, when the inventions are conceptually very close. In those cases, the examiner may decide to complete the international search and written opinion for the additional invention(s) together with that for

the invention first mentioned. In considering the amount of work involved, the examiner should take into account the time taken to create the written opinion as well as that needed to perform the search, since even when the analysis involved as regards the search is negligible, the opposite may be the case for the written opinion of the International Searching Authority and therefore justify requesting the additional fees. If it is considered that the total additional work does not justify requesting additional fees, all results are included in the international search report without inviting the applicant to pay an additional search fee in respect of the additional inventions searched, but stating the finding of lack of unity of invention.

#### *Protest Procedure*

*Rule 40.2(c)*

10.66 The applicant may protest the allegation of lack of unity of invention, or that the number of required additional fees is excessive and request a refund of the additional fee(s) paid. If, and to the extent that, the International Searching Authority finds the protest justified, the fee(s) are refunded. (The additional search fees must be paid for any protest to be considered.)

*Rule 40.2(c)*

10.67 Protest of allegation of lack of unity is in the form of a reasoned statement accompanying payment of the additional fee, explaining why the applicant believes that the requirements of unity of invention are fulfilled and fully taking into account the reasons indicated in the invitation to pay additional fees issued by the International Searching Authority.

*Rule 40.2(c)*

10.68 The protest is examined by a three-member board or other special instance of the International Searching Authority or any competent higher authority, and a decision taken on it. To the extent that the applicant's protest is found to be justified, the additional fee is totally or partly reimbursed. At the request of the applicant, the texts of both the protest and the decision on it are notified to the designated Offices together with the international search report (see paragraph 10.70).

*Rule 40.2(c) to (e)*

10.69 Where the applicant has paid an additional fee under protest, the International Searching Authority may require the applicant also to pay a fee for the examination of the protest ("protest fee"). Details of the protest fee, if any, charged by the International Searching Authorities appear in Annex D of the *PCT Applicant's Guide*, Volume I – Introduction to the International Phase. If a protest fee is chargeable by the International Searching Authority, it is only required in a particular case after a prior review of the justification for the invitation to pay additional search fees. The review should not be made by the examiner who made the finding alone. If the invitation to pay additional fees is maintained, the applicant is invited to pay the protest fee within one month from the date of the notification to the applicant of the result of the review. The notification of the result of the review, if negative, gives a technical reasoning of that result. If the protest fee is not paid, the protest is considered withdrawn. The protest fee is refunded to the applicant under Rule 40.2(e) where the three-member board, special instance or higher authority finds that the protest was entirely justified. The applicant may, on the payment of the protest fee, supplement the reasoned statement which accompanied the protest, taking into consideration the result of the review.

*Rule 40.2(c); Section 502*

10.70 Where the applicant paid additional search fee(s) under protest, he is informed promptly (Form PCT/ISA/212 may be used for that purpose) of any decision about the

compliance with the requirement of unity of invention. At the same time the International Searching Authority transmits to the International Bureau a copy of the protest and of the decision thereon as well as any request by the applicant to forward the texts of both the protest and the decision thereon to the designated Offices.

#### **Process at the International Preliminary Examination Stage**

*Article 34(3)(a) to (c); Rule 68*

10.71 The procedure before the International Preliminary Examining Authority regarding lack of unity of invention is governed by Article 34(3)(a) to (c) and Rule 68 (see also Rule 70.13). This procedure is more fully explained in paragraphs 10.74 to 10.76. It should be noted that in most instances lack of unity of invention will have been noted and reported upon by the International Searching Authority, which will have drawn up an international search report and written opinion based on those parts of the international application relating to the invention, or unified linked group of inventions, first mentioned in the claims ("main invention"), unless the applicant has paid additional fees.

10.72 If the applicant has not availed himself of the opportunity to have the international search report issued on at least some of the other inventions, this must be taken as an indication that the applicant is prepared for the international application to proceed on the basis that it relates to the invention first mentioned in the claims as originally contained in the international application as filed.

10.73 However, whether or not the question of unity of invention has been raised by the International Searching Authority, it may be considered by the examiner during international preliminary examination. In his consideration, he should take into account all the documents cited in the international search report and any additional documents considered to be relevant.

*Rule 68.2, 68.3*

10.74 Where the examiner finds a lack of unity of invention, a communication may, at the option of the examiner (see paragraph 10.76), be sent to the applicant, using Form PCT/IPEA/405, informing him why there is a lack of unity of invention and inviting him within a period stated in the invitation (the period may be between one and two months from the date of the invitation), either to restrict the claims or to pay an additional fee for each additional invention claimed. Where such a communication is sent, at least one possible restriction, which would avoid the objection of lack of unity of invention, is indicated by the examiner. In the invitation to pay additional fees, the examiner sets out a logically presented, technical reasoning containing the basic considerations behind the finding of lack of unity in accordance with these Guidelines.

*Article 34(3)(c); Rule 68.4, 68.5*

10.75 If the applicant does not comply with the invitation (by not paying the additional fees or by not restricting the claims either sufficiently or at all), the international preliminary examination report is established on those parts of the international application which relate to what appears to be the "main invention" and the examiner indicates the relevant facts in such report. In cases of doubt as to which is the main invention, the invention first mentioned in the claims is considered the main invention.

*Rule 68.1, 68.3(c) to (e); Section 603*

10.76 However, there are cases of lack of unity of invention where, compared with the procedure of inviting the applicant to restrict the claims or to pay additional fees (Rule 68.2), no or little additional effort is involved in establishing the international preliminary examination report for the entire international application. Then, reasons of economy may make it advisable for the examiner to avail himself of the option referred to in Rule 68.1 by